Carbapenem-resistant Acinetobacter baumannii complex in the United States - an epidemiological and molecular description of isolates collected through the Emerging Infections Program, 2019.

Acinetobacter baumannii Emerging Infections Program antimicrobial drug resistance carbapenem-resistant molecular epidemiology surveillance

Journal

American journal of infection control
ISSN: 1527-3296
Titre abrégé: Am J Infect Control
Pays: United States
ID NLM: 8004854

Informations de publication

Date de publication:
29 Apr 2024
Historique:
received: 29 12 2023
revised: 14 04 2024
accepted: 15 04 2024
medline: 2 5 2024
pubmed: 2 5 2024
entrez: 1 5 2024
Statut: aheadofprint

Résumé

Understanding the epidemiology of carbapenem-resistant A. baumannii complex (CRAB) and the patients impacted is an important step towards informing better infection prevention and control practices and improving public health response. Active, population-based surveillance was conducted for CRAB in 9 U.S. sites from January 1-December 31, 2019. Medical records were reviewed, isolates were collected and characterized including antimicrobial susceptibility testing and whole genome sequencing. Among 136 incident cases in 2019, 66 isolates were collected and characterized; 56.5% were from cases who were male, 54.5% were from persons of Black or African American race with non-Hispanic ethnicity, and the median age was 63.5 years. Most isolates, 77.2%, were isolated from urine, and 50.0% were collected in the outpatient setting; 72.7% of isolates harbored an acquired carbapenemase gene (aCP), predominantly bla Our surveillance found that CRAB isolates in the U.S. commonly harbor an aCP, have an antimicrobial susceptibility profile that is defined as difficult-to-treat resistance, and epidemiologically are similar regardless of the presence of an aCP.

Sections du résumé

BACKGROUND BACKGROUND
Understanding the epidemiology of carbapenem-resistant A. baumannii complex (CRAB) and the patients impacted is an important step towards informing better infection prevention and control practices and improving public health response.
METHODS METHODS
Active, population-based surveillance was conducted for CRAB in 9 U.S. sites from January 1-December 31, 2019. Medical records were reviewed, isolates were collected and characterized including antimicrobial susceptibility testing and whole genome sequencing.
RESULTS RESULTS
Among 136 incident cases in 2019, 66 isolates were collected and characterized; 56.5% were from cases who were male, 54.5% were from persons of Black or African American race with non-Hispanic ethnicity, and the median age was 63.5 years. Most isolates, 77.2%, were isolated from urine, and 50.0% were collected in the outpatient setting; 72.7% of isolates harbored an acquired carbapenemase gene (aCP), predominantly bla
CONCLUSIONS CONCLUSIONS
Our surveillance found that CRAB isolates in the U.S. commonly harbor an aCP, have an antimicrobial susceptibility profile that is defined as difficult-to-treat resistance, and epidemiologically are similar regardless of the presence of an aCP.

Identifiants

pubmed: 38692307
pii: S0196-6553(24)00458-9
doi: 10.1016/j.ajic.2024.04.184
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Published by Elsevier Inc.

Auteurs

Sandra N Bulens (SN)

Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: zgf6@cdc.gov.

Davina Campbell (D)

Centers for Disease Control and Prevention, Atlanta, GA, United States.

Susannah L McKay (SL)

Centers for Disease Control and Prevention, Atlanta, GA, United States.

Nicholas Vlachos (N)

Centers for Disease Control and Prevention, Atlanta, GA, United States.

Alex Burgin (A)

Centers for Disease Control and Prevention, Atlanta, GA, United States.

Mark Burroughs (M)

Centers for Disease Control and Prevention, Atlanta, GA, United States.

Jasmine Padila (J)

Centers for Disease Control and Prevention, Atlanta, GA, United States.

Julian E Grass (JE)

Centers for Disease Control and Prevention, Atlanta, GA, United States.

Jesse T Jacob (JT)

Georgia Emerging Infections Program, Decatur, GA; Emory University School of Medicine, Atlanta, GA.

Gillian Smith (G)

Georgia Emerging Infections Program, Decatur, GA; Emory University School of Medicine, Atlanta, GA; Atlanta Veterans Affairs Medical Center, Decatur, GA.

Daniel B Muleta (DB)

Tennessee Department of Health, Nashville TN.

Meghan Maloney (M)

Connecticut Department of Public Health, Hartford, CT.

Bobbie Macierowski (B)

Connecticut Department of Public Health, Hartford, CT.

Lucy E Wilson (LE)

Maryland Department of Health, Baltimore, Maryland; University of Maryland Baltimore County, Baltimore, Maryland.

Elisabeth Vaeth (E)

Maryland Department of Health, Baltimore, Maryland.

Ruth Lynfield (R)

Minnesota Department of Health, St. Paul, MN.

Sean O'Malley (S)

Minnesota Department of Health, St. Paul, MN.

Paula M Snippes Vagnone (PM)

Minnesota Department of Health, St. Paul, MN.

Jennifer Dale (J)

Minnesota Department of Health, St. Paul, MN.

Sarah J Janelle (SJ)

Colorado Department of Public Health and Environment, Denver, CO.

Christopher A Czaja (CA)

Colorado Department of Public Health and Environment, Denver, CO.

Helen Johnson (H)

Colorado Department of Public Health and Environment, Denver, CO.

Erin C Phipps (EC)

University of New Mexico, Albuquerque, NM; New Mexico Emerging Infections Program, Santa Fe, NM.

Kristina G Flores (KG)

University of New Mexico, Albuquerque, NM; New Mexico Emerging Infections Program, Santa Fe, NM.

Ghinwa Dumyati (G)

University of Rochester Medical Center, Rochester, New York.

Rebecca Tsay (R)

University of Rochester Medical Center, Rochester, New York.

Zintars G Beldavs (ZG)

Oregon Health Authority; Portland, OR.

P Maureen Cassidy (P)

Oregon Health Authority; Portland, OR.

Amanda Hall (A)

Centers for Disease Control and Prevention, Atlanta, GA, United States.

Maroya S Walters (MS)

Centers for Disease Control and Prevention, Atlanta, GA, United States.

Alice Y Guh (AY)

Centers for Disease Control and Prevention, Atlanta, GA, United States.

Shelley S Magill (SS)

Centers for Disease Control and Prevention, Atlanta, GA, United States.

Joseph D Lutgring (JD)

Centers for Disease Control and Prevention, Atlanta, GA, United States.

Classifications MeSH